drugset / Trial / NCT07101627
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
Phase 2
Not yet recruiting
149 enrolled
Shanghai Pulmonary Hospital, Shanghai, China
Jiangsu HengRui Medicine Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate the efficacy and safety of Hetrombopag in secondary prevention of thrombocytopenia caused by lung cancer treatment
Timeline
- Start
- 2025-08-01
- Primary completion
- 2027-04-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hetrombopag | Small molecule | 7.5 mg | Oral |